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In major depression, when a ﬁrst antidepressant does not cause remission of symptoms
(60%–75%), there are several options for continuing treatment in the next step. This study is a
cost-utility analysis (CUA) of different second-line approaches. In a simulated trial outpatients
with MDD were treated with citalopram for 13 weeks (level 1), then based on two alternative
algorithms implemented from the Sequenced Treatment Alternatives to Relieve Depression
(STAR*D) study. Algorithm A: citalopram was continued until study endpoint (week 26).
Algorithm B: patients who remitted during level 1 continued citalopram. Those who did not
remit could opt for switching to another antidepressant (venlafaxine; sertraline) (b1) or adding
bupropion to citalopram treatment (augmentation; b2). Algorithm B increased remission rate
by 10.6% over Algorithm A (number needed to treat: 9.9; sensitivity range: 9.1–12.5). As a
comparison, differences between active antidepressants and placebo are associated with NNT
values of 6 to 8. In CUA Algorithm B was dominant with an ICER of $11,813 (sensitivity range=
$1783 – $21,784), which is o1 GDP per capita cost-effectiveness threshold (USA=$47,193).
Among Algorithm B options, switching (b1) dominated Algorithm A with a smaller number of
responders than augmentation approach (b2) (NNT 11 vs. 7.7), whereas ICER values were similar
(b1: $14,738; b2: $15,458). However we cannot exclude a bias in selecting second treatment.
This cost-utility analysis shows (in line with current guidelines) a beneﬁt in modifyingElsevier B.V. and ECNP. All rights reserved.
o.2013.08.008
1 6584237; fax: +39 051 521030.
@unibo.it (A. Serretti).
P. Olgiati et al.1740antidepressant treatment if response to ﬁrst-line agent does not occur within 3 months, but not
a clear-cut evidence in terms of NNT.
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1.1. Burden related to major depression and
response to treatment
Major depressive disorder (MDD) is the most common mental
disorder, affecting approximately 1 in 5 adults worldwide,
and the fourth major cause of disability (Ustun et al., 2004).
Societal costs are considerable in terms of health expendi-
ture (Watkins et al., 2009) and work days lost (Bender and
Farvolden, 2008; Rytsala et al., 2005). Moreover depressed
patients are characterized by health-related quality of life
inferior to the general population (Aydemir et al., 2009;
Sapin et al., 2004), and comparable with the burden in
severe physical disorders (Buist-Bouwman et al., 2006;
Soeteman et al., 2005). Antidepressant drugs not only treat
depressive manifestations but they can also improve quality
of life (Llorca and Fernandez, 2007; Sarnes and Frankum,
2004). Nevertheless only 25–40% of patients on pharmaco-
logical treatment achieve full remission of symptoms in real
world conditions (Cuffel et al., 2003), whereas 60–75% of
them do not reach ideal treatment outcome.
1.2. Sequential approach to treatment resistant
depression
Current guidelines are made to change antidepressant
treatment if there is no adequate response after 6–8 weeks
(American Psychiatric Association Practice Guidelines.
Available at http://psychiatryonline.org). In the large
Sequenced Treatment Alternatives to Relieve Depression
(STARnD) study (www.star-d.org), that was funded by the
NIMH, the patients completed 13 weeks on a treatment
regimen. If they failed to achieve remission within this
cycle, their treatment was modiﬁed and they entered
another cycle. At the end of four sequenced cycles approxi
mately two thirds of the STARnD sample remitted (Rush
et al., 2006). This was used to support sequential approach
to treat resistant depression. However in the STARnD sample
most patients responded after 6 weeks of treatment.
Similarly delayed response was the most common pattern
of antidepressant response in the large GENDEP study (Uher
et al., 2011). In long-term antidepressant trials, responding
to treatment within the ﬁrst 2 months was associated with a
greater probability of achieving remission after 6 months
(Wade et al., 2009). Another study demonstrates that
remission rate during SSRI treatment increases from week
8 to week 52 (Wade et al., 2006). This body of evidence
suggests that in some depressed patients symptoms might
decrease slowly and improvements occur long after three
months of treatment. In addition since Kraepelin's era it has
been acknowledged that major depression is a recurrent
disorder and it is possible to recover from an episode within
6–8 months without treatment (Fox, 2002). Although spontaneous remissions are more likely in the ﬁrst weeks of
depression (Posternak et al., 2006), there could be a
substantial increase in such cases months later by effect
of their accumulation over time. Thus if the patient under
goes sequenced trials, each lasting a few months, increase
in remission is not necessarily due to treatment change but
it might reﬂect the spontaneous course of depressive
episode towards recovery.
1.3. Objectives of cost-utility analysis
In this study we compared the ﬁrst two steps of STARnD to
an alternative scenario, not implemented in STARnD, in
which patients with MDD were treated with the same SSRI
for 26 weeks. This accounted for delayed response to
antidepressant treatment and spontaneous remission, albeit
estimated in a theoretical way. We performed a cost-utility
analysis (CUA) on these scenarios. Secondly we compared
switching and augmentation arms of STARnD.
2. Experimental procedures
2.1. Sample and setting
The sample was made by STARnD cohort of about 3000 adult
outpatients (age 18–75 years) with major depressive disorder.
Diagnostic assessment was performed by the treating physician
using a non-structured interview and conﬁrmed by a DSM IV based
checklist. Exclusion criteria were indications for hospital treatment
such as psychotic symptoms, suicidal risk or inpatient detoxiﬁcation
for alcohol/substance dependence. Women who were pregnant or
breastfeeding were also excluded. Obsessive compulsive disorder
and eating disorder require different treatment options, therefore
these comorbidities were also reasons for no inclusion. The severity
of depressive symptoms was assessed by the 17-item version of the
Hamilton Rating Scale for Depression (HAMD17). A score greater
than or equal to 14 was required for inclusion. The cohort's
characteristics are reported in Table 1. The STARnD was a chronic
depressive sample. The mean duration of a depressive episode was
150 weeks. Patients were treated in primary care centers (PCC) or
community-based mental health centers (CMHC) in the United
States.
2.2. Pharmacological treatment decision tree
Our STARnD based decision tree (Rush et al., 2006) included two
treatment levels (see Figure 1).
2.2.1. Level 1
All patients were treated with citalopram for 13 weeks. The starting
dose was 10 mg/d. Citalopram was titrated to reach the target dose
(40 mg/d) within 4 weeks. Citalopram was lowered by 10 mg/d if
there were side-effects. Conversely the citalopram dose was
increased to 50 mg/d if there was no partial response (HAMD
decrease o25%). Average citalopram dose was 41.8716.8 mg
per diem.
Table 1 Characteristics of the cohort.
mean7SD %
Age 40.8713.0
Women 0.64
Never married 0.29
Education years 13.473.2
Unemployed 0.38
Recurrent MDD 0.75
Number of episodes 6.0711.4
Length of illness (yrs) 15.573.2
Length of current episode (mos) 24.6751.7
Axis I comorbidity 0.35
STARnD sample (Rush et al., 2006).
Figure 1 Pharmacological treatment. All patients were treated
with citalopram for 13 weeks (level 1). Then two algorithms were
implemented for subsequent 13 weeks: Algorithm A: level 1 treat-
ment was continued until endpoint. Algorithm B: the patients who
achieved remission within level 1 continued with citalopram—the
others could opt for switching to sertraline/venlafaxine (b1) or
adding bupropion to citalopram treatment (b2).
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This level was available for patients who completed level 1. Two
alternative scenarios or algorithms were implemented for this
13-week lasting level.
Algorithm A. All patients included in level 2, both remitters and
those who did not remit during level 1, were treated with
citalopram for a further 13 weeks.
Algorithm B. Patients who were in remission (HAMDo7) at level
2 intake remained on citalopram until endpoint. Instead those who
were not in remission were allowed to choose their next treatment
according to an equipoise design. They opted for either treatment arm:
b1 (switch): citalopram was stopped; each patient was rando-
mized to receive sertraline (100–200 mg/d: mean 135 mg) or
venlafaxine (150–300 mg/d: mean 193 mg);b2 (augmentation): citalopram was continued as in level 1;
bupropion (150–300 mg/d: mean 267 mg) was added to SSRI
treatment. Based on STARnD results we projected that 58% of
the cohort would switch therapy and 42% would choose
augmentation (Rush et al., 2006).
2.3. Outpatient visits
The frequency of visits, established according to published guide-
lines (CG90 Depression in adults: NICE guidelines. Available at
http://guidance.nice.org.uk) and similar to psychiatric practice in
the United States, was once every 2 weeks in the ﬁrst 3 months. In
subsequent months the frequency ranged from once every 2 weeks
in non-responders to once a month in those who achieved remission.
The patients were visited by a physician. The ﬁrst visit, aimed at a
thorough diagnostic assessment, lasted approximately 1 h. Subse
quent visits, in which the physician brieﬂy assessed depressive
symptoms and side effects related to medications, lasted 20 min.
2.4. Costs
We analyzed direct costs for drug acquisition and delivery and costs
for visits in outpatient services Table 2. Information on drug prices
was collected from Red Book (http://sites.truvenhealth.com/red
book) (average wholesale prices AWP; 20% discount applied to
government institutions). Cost for outpatient care was based on
World Health Organization data (WHO-CHOICE project. www.who.
int/choice/en/). Community mental health centers were assumed to
be equivalent to primary care centers. So the estimated cost for
outpatient visit is similar to cost reimbursed by Medicare program
that is approximately 60% of psychiatric visit fees. Cost data were
referred to 2011. Costs for outpatient visits were available for 2008.
They were adjusted to 2011 costs using OECD data (http://stats.
oecd.org/) on average annual inﬂation in the 3 year period: United
States, 1.5%. Indirect costs related to productivity loss were not
included in CUA, as recommended in the guidelines for pharmacoe
conomic analysis (Weinstein et al., 1996). In fact they were likely to
be captured in the utility weights assigned to patients of depressive
state, and would therefore be double counted if included as costs as
well (Table 2).
2.5. Markov model and utilities
The Markov approach is often used to predict the probability
distribution of a certain variable (i.e. disease progression) in a
multi-state model. The model requires the knowledge or the
estimation of the probabilities of transition for each change of
state. Given the distribution of the initial state, each of the next
states' probability distribution is obtained via a transition matrix
that is the structure of the conditional probabilities. As an
important assumption, Markov property states that the conditional
probabilities at future steps depend univocally on the current and
not on the previous states. When a model is applied to medical
decision making, a disease course is divided into distinct states;
transitions probabilities are assigned for movement between these
states over a discrete time period (Markov cycle). By attaching
estimates of resource use and health outcome consequence to
states and transitions in the model, then running it over a number
of cycles, it is possible to estimate long-term costs and outcomes
associated with a disease and a particular health intervention. In
this study a Markov model was developed in Microsoft Excel to
analyze transitions from depression to remission state, and from
remission and nonremission to drop out state. Dropout patients
either remitted or continued to be in depression. Remitting patients
Table 2 Direct Costs (USD, 2011).
Baseline Range Sources
Drugs (3 months)
Citalopram (41.7 mg/d) 193 96–289 AWP (Red Book)
Bupropion (267 mg/d) 354 177–531 AWP (Red Book)
Venlafaxine (193 mg/d) 375 187–561 AWP (Red Book)
Sertraline (135 mg/d) 304 152–456 AWP (Red Book)
Outpatient visit 55 27.5–82.5 World Health Organization (WHO-CHOICE project)
ICER thresholds based on gross domestic product (GDP) per capita (WHO-CHOICE methodology)
Very cost-effective (o1GDP per capita) 47,193
Cost-effective (o3GDP per capita) 141,179
AWP (average wholesale price) refers to the average value at which wholesalers sell drugs to physicians, pharmacies and other
providers (USA). Red Book (http://sites.truvenhealth.com). WHO-CHOICE (Choosing Interventions that are Cost-Effective): a World
Health Organization (WHO) initiative developed in 1998 with the objective of providing policy makers with cross-country data on
cost-beneﬁt of health interventions (http://www.who.int/choice/en/).
Incremental Cost-Effectiveness Ratio (ICER): (Cost BCost A)/(QALY BQALY A), A=treatment A, B=treatment B, LL= lower limit,
UL=upper limit, SE=standard error, SD=standard deviation.
All costs are expressed in US dollars (2011). Costs are normally distributed. Mean is set equal to the baseline value. The lower limit
(LL) and upper limit (UL) of distribution, reported in brackets, are set to 0.5 times and 1.5 times the baseline value, respectively.
Standard error (SE), equal to standard deviation, is calculated as follows: SE=(UL-LL)/(1.96 2).
Costs for visits are drawn from the WHO_CHOICE (see above) These costs, available for year 2008, are inﬂated by mean annual
inﬂation rate observed in OECD countries during the period 2009-2011: United States: 1.5% (total increase: 4.5%).
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(non-remission 
relapse) 
REMISSION DROPOUT 
(no treatment) 
Figure 2 Markov model states. This ﬁgure shows Markov states
and represented transitions from one state to another (arrows)
in a Markov cycle. Acute depression, non-remission and relapse
were assigned the same utility score, thus they were repre-
sented as one state. Patients were initially in acute depression,
then they could remit or remain depressed. Both remitting
individuals and those who did not remit could drop out from
treatment. Remitting patients (including those who had dis-
continued their treatment) could relapse.
P. Olgiati et al.1742could relapse. Relapse and nonremission were considered to be
equal to acute depression (see Figure 2). Suicide was not repre-
sented. The structure of Markov model included four 6.5 weeks
lasting cycles. We hypothesized that all patients were in acute
depression within cycle 1. At the end of this cycle transitions
occurred by effect of level 1 treatment, and the proportions of
remitting, not remitting and dropout patients were not modiﬁed in
cycles 2 and 3. Health state probabilities were expected to changeat the end of cycle 3 because of level 2 treatment. These
probabilities were used to model cycle 4. For each cycle transition
probabilities were included in a matrix, then cumulative probabil-
ities across all cycles were estimated by performing matrix product.
Probabilities were estimated from STARnD and other published
studies (see Table 3). Each health state was assigned a utility score
to reﬂect the amount of quality of life attached to it. Utility scores
were differentiated by health conditions and treatment-related
conditions as follows (Revicki and Wood, 1998): acute depression,
nonremission and relapse=0.4; remission=0.9; treatment-related
burden=0.04 (see Table 3).2.6. Cost-utility analysis
Cost and utility data were processed along with Markov cycle
transitions. This allowed the calculation of overall cost and
quality-adjusted life years (QALY) associated with Algorithms A
and B. The acceptability of the dominant algorithm was established
in terms of incremental cost-effectiveness ratio (ICER), which is
deﬁned as the ratio of the change in costs of a therapeutic
intervention, compared to the alternative, to the change in effects
of the intervention, according to the formula: (Cost Algorithm B
Cost Algorithm A)/(QALY Algorithm BQALY Algorithm A).
A secondary analysis differentiated between switching arm (b1)
and augmentation arm (b2) of Algorithm B, which were compared to
Algorithm A. Sensitivity analysis was carried out to deal with
uncertainty in base-case estimates of model parameters. Each
parameter was assigned a probability distribution, normal distribu-
tion for continuous variables such as drug dosages, number of
outpatient visits and costs. Probabilities and utilities, which vary
over a 0–1 range, should have beta-distribution (Andronis et al.,
2009). Baseline values, estimated from literature and ofﬁcial
sources (see above), were assumed to be the means of distribu-
tions. The lower and upper limits of variation ranges were
established as reported in Table 3, similar to previous publications
(Olgiati et al., 2012; Serretti et al., 2011). Probabilistic sensitivity
analysis (Monte Carlo) accounted for interactions between the
whole parameters and generated a probability distribution of ICER
Table 3 Probabilities (3 months) and utility scores.
Baseline Range Sources
Probabilities
Remission (level 1) 0.27 0.20–0.41 STARnD (Rush et al., 2006)
Remission (level 2;
Algorithm A)
0.07 0.05–0.09 52 weeks SSRI trial (Wade et al., 2006) In this sample
remissions increased from 2.5% per week
in the ﬁrst eight weeks to 0.4% in subsequent weeks
Remission (level 2;
Algorithm B)
0.30 0.23–0.45 STARnD (Rush et al., 2006)
(algorithm b1) 0.27 0.21–0.33 STARnD (Rush et al., 2006)
(algorithm b2) 0.35 0.26–0.53 STARnD (Rush et al., 2006)
Remission (no
treatment)
0.05 0.04–0.07 Prospective naturalistic study. Survival analysis
of untreated depression (Posternak et al., 2006)
Dropout (level 1) 0.26 0.19–0.40 STARnD (Warden et al., 2007)
Dropout (level 2) 0.23 0.17–0.35 STARnD (Warden et al., 2009)
Relapse (treatment) 0.05 0.04–0.07 Model of depression implemented for cost-utility
analysis (Perlis et al., 2009)
Relapse (no treatment) 0.13 0.10–0.19 Model of depression implemented for cost-utility
analysis (Perlis et al., 2009)
Utility scores
Acute depression / relapse 0.40 0.30–0.60 (Revicki and Wood, 1998)
Remitted depression 0.90 0.68–1.00 (Revicki and Wood, 1998)
Treatment-related disutility 0.04 0.03–0.06 (Revicki and Wood, 1998)
LL= lower limit, UL=upper limit, SE=standard error, SD=standard deviation.
Sensitivity analysis. Probabilities and utilities have beta distribution. Baseline value corresponds to the mean of distribution. The LL is
set equal to 0.75 times the baseline value. The difference between the baseline value and the LL is assumed to be 1/3 the difference
between the UL and LL (Golenko-Ginzburg, 1988). SE (equal to SD) is calculated as (UL-LL)/2 1.96. Slope parameters α and β are
estimated as follows: mean=α⧸(α+β) and SD= √(αβ)⧸(α+β) (α+β) (22).
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variables were interrelated as in naturalistic contexts: side-effect
burden and the likelihood of discontinuing antidepressant treat-
ment (Machado et al., 2006); patient's age and delayed (after
3 months) response to treatment (Driscoll et al., 2005); symptom
severity at treatment intake and antidepressant response (Kirsch
et al., 2008). 100,000 trials were run for simulation using the
commercial software Crystal Ball by Oracle (www.oracle.com). One
way sensitivity analysis was performed to identify which parameters
could signiﬁcantly affect cost-utility.3. Results
3.1. Remission and dropout rates for control
scenario (Algorithm A)
The cumulative rate of remission for control scenario, in
which antidepressant treatment was unchanged for 26
weeks (Algorithm A), was equal to 34.6% and it varied from
33.7% to 36.5% based on sensitivity ranges reported in
Table 3. Dropout rate was estimated to be 44.8%.3.2. Remission and dropout rates for Algorithm B
(b1 and b2)
The cumulative rate of remission for STARnD based scenario, in
which antidepressant treatment was changed for those notremitting within 13 weeks (Algorithm B), was equal to 45.2%.
This value was 10.6% greater than what was estimated for
Algorithm A. The difference corresponded to a number needed
to treat (NNT) of 9.9 when those algorithms were compared.
Considering the lower and upper limits of remission achieved
by applying Algorithm A as reported below, NNT varied from
9.1 to 12.5. Algorithm B dropout rate was 45%. Algorithm b1
(switching approach) was associated with a remission prob-
ability of 43.95%, which corresponded to a NNT of 11.2
compared to Algorithm A. Algorithm b2 (augmentation) was
associated with a remission probability of 47.5% (NNT=7.7).3.3. Cost-utility analysis
Algorithm B overall cost was $800.33. Incremental cost
over Algorithm A was $75.92 necessary to produce 0.007
more QALYs. Based on these results, ICER was equal to
$11,481. In probabilistic sensitivity analysis mean ICER value
was $10,66572,126 (95%CI: 6498–14,832). Utility scores
assigned to depression and remission states and the prob-
ability of achieving remission after 3 months of treatment
(Algorithm A) had the strongest impact on ICER variation.
However these variables could not shift ICER value above
1GDP threshold (Table 4), which is suggested as a cost-
effectiveness threshold (see discussion). Algorithm b1 pro-
duced 0.006 more QALYs than Algorithm A at an incremental
cost of $84.74. This corresponded to an ICER of $14,738.
Table 4 One way sensitivity analysis.
Range ICER
Algorithm A remission 0.05–0.11 10,457–14,176
Utility for acute depression 0.30–0.60 9567–19,135
Utility for remitted
depression
0.68–1.00 20,502–9568
Cost of citalopram 96.0–289 15,120–7842
Cost of bupropion 177–531 7162–15,800
Cost of venlafaxine 187–561 8322–14,640
Cost of sertraline 152–456 8920–14,042
Only factors that produce 4$500 ICER variations over base-
line value are reported.
P. Olgiati et al.1744The difference between algorithms b2 and A was 0.008
QALYs, whereas incremental cost was $124.44 (ICER=
$15,458).4. Discussion
4.1. Changing antidepressant treatment vs.
leaving it unchanged
STARnD is a pivotal study in the ﬁeld of treatment resistant
depression; however its greatest limitation is the lack of a
control arm in which ﬁrst-line antidepressant is maintained
for several months compared to the existing level 2 steps.
We integrated this scenario (Algorithm A) in a theoretical
model and analyzed its ﬁndings as number needed to treat
and cost-utility ratio. In clinical terms our simulation
indicates that 9–12 individuals should have modiﬁed their
antidepressant treatment if not remitting within 3 months
to achieve one more remission than those remaining on the
same treatment for 6 months. This is not consistent with
a clear-cut difference favoring sequenced treatment
approach to resistant depression as a NNTo10 was sug-
gested as a threshold of clinical signiﬁcance by the National
Institute of Clinical Excellence, UK. Moreover NNT values of
6 to 8 were reported in SSRI–placebo comparisons [Thase,
2011 #224]. On the other hand even a small beneﬁt in
clinical response might be valuable for quality of life and
subjective well being, and this might justify increased costs.
In fact our analysis showed that changing antidepressant
treatment would allow a gain of 0.007 QALYs at an incre-
mental cost of 76$. This corresponds to $11,481 spent (ICER)
to achieve one more QALY. This is an excellent result based
on cost-effectiveness thresholds commonly in use. For
example, the World Health Organization suggests gross
domestic product (GDP) per capita as a reliable measure
in cost-effectiveness studies (http://www.who.int/choice)
Thus an intervention is dominant over the alternative one if
ICER emerging from their comparison is below 1 GDP per
capita, and it is still moderately cost-effective if ICER is
between 1 and 3 GDP per capita. In the United States, GDP
per capita was estimated to be $47,193 in 2011. (http://
stats.oecd.org).4.2. Changing strategies: switching vs.
augmentation
Our simulation shows that switching to a different anti-
depressant medication if there is no remission within 13
weeks is associated with a smaller clinical beneﬁt than
taking the same antidepressant for the following weeks with
the addition of another agent (NNT: 11 vs. 7.7). Switching
strategy is less favorable, perhaps because the onset of
antidepressant response continues over the ﬁrst months of
treatment but late response cannot be seen when the
antidepressant is changed. So an antidepressant must be
taken for a long period to maximize its therapeutic effects.
These results echoed those of two studies on treatment
resistant depression carried out at different university sites
across Europe. In the ﬁrst study no advantage was reported
for switching to a different class of antidepressants instead
of continuing on the same class (Souery et al., 2011a). In the
second work switching from a SSRI to a TCA or vice versa
was associated with a marginally worse outcome than
staying on the same antidepressant (Souery et al., 2011b).
However we note that in STARnD the choice of delivering
antidepressant treatment according to an equipoise design
(patients were allowed to opt for their preferred solution)
could have inﬂated the beneﬁt of augmentation approach.
Indeed patients with at least a moderate improvement on
citalopram treatment were more likely to continue this
medication.4.3. Strengths and limitations of the model
We acknowledge that it is possible to remit from a major
depressive episode after 3 months of treatment. In those
who have not modiﬁed their treatment, remitting could be
due to delayed onset response to antidepressant medication
but also to spontaneous remission once treatment effect has
disappeared. Spontaneous remission is dependent on the
untreated period. It is approximately 10–20% after 3–6
months of illness and no treatment (Posternak and Miller,
2001; Whiteford et al., 2012); however the longer the
depressive episode, the lower the probability of sponta-
neous remission (Whiteford et al., 2012). In our cohort the
length of episode averaged 24 months and this suggested a
low spontaneous remission. Late response to antidepressant
treatment and spontaneous remission had modest effect
sizes in our model, yet their impact was not negligible on
remission rate. Therefore we included these data. Some
characteristics of our study limit the generalization of its
results. State transition model did not account for the
risk of suicide. This was estimated to be 4/10,000 over a
6-month period (Simon et al., 2006). Acute depression
before treatment and lack of remission during treatment
were assigned the same utility score. This does not account
for patients who fail to remit but partially respond to
treatment. Nevertheless sensitivity analysis was performed
on a wide utility range that should encompass both patients
in acute depression and those who are not in remission but
have an improvement in depressive symptoms. The study
failed to document prior antidepressant treatments which,
however, cannot be excluded. Some treatment choices
based on STARnD algorithms are relatively common in
1745Cost-utility and treatment resistant depressionpsychiatric practice in the United States, but this is not
warranted for other countries. In particular citalopram
may not be an ideal ﬁrst-line treatment for depression.
A number of studies state that, for instance, escitalopram
and venlafaxine are stronger antidepressants (Cipriani
et al., 2007). STARnD was a chronic depressive sample
(length of current episode up to 150 weeks; length of illness
15 years; 75% recurrent depression) and in most patients
there were other axis I disorders. Thus our ﬁndings might
not be applicable to samples with different characteristics.
4.4. Conclusions
The results of this cost-utility analysis are consistent with
current guidelines suggesting that antidepressant treatment
should be modiﬁed after 3 months of insufﬁcient response.
However there might be less advantage for this approach
than generally acknowledged, and it is necessary to com-
bine symptomatic improvement, quality of life and costs to
demonstrate its dominance over continuing with ﬁrst-line
treatment. Late response to antidepressant treatment,
though modest, and the likelihood of spontaneous remission
contribute to symptomatic outcome in acute phase treat-
ment. Late response is common in elderly patients (Driscoll
et al., 2005; Fischer et al., 2003). Spontaneous remission is
more likely in the ﬁrst weeks of depressive disorder, but it
still occurs at a substantial rate in patients who have been
depressed for 3–12 months (Posternak et al., 2006). In this
group of patients who are early on treatment, but after 3
months of illness, and in elderly depressed patients any
approach to treatment resistant depression should be
compared with a control strategy of continuing one anti-
depressant for several weeks.
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